Research Summary

Effect of Dual PDE3/4 Inhibitor Amixetrine on Exacerbation Rate and Risk in Moderate to Severe COPD

Edited by:
Anthony Calabro, MA

Key Highlights

  • Ensifentrine reduced moderate to severe COPD exacerbation rates by 41% over 24 weeks compared with placebo.
  • Time to first exacerbation was significantly delayed, with a 41% reduction in exacerbation risk.
  • Treatment effects were consistent across demographic and clinical subgroups.
  • Numerical delays in progression from infrequent to frequent exacerbator status were observed.

Ensifentrine significantly reduced chronic obstructive pulmonary disease (COPD) exacerbations in a prespecified pooled analysis of the ENHANCE-1 and ENHANCE-2 phase 3 trials, according to findings published in CHEST. Exacerbation prevention remains a central priority in COPD management because these events accelerate loss of lung function, worsen quality of life, and increase mortality risk.

Investigators pooled modified intention-to-treat data from ENHANCE-1 and ENHANCE-2, randomized, double-blind, placebo-controlled trials evaluating twice-daily nebulized ensifentrine 3 mg over 24 weeks in adults aged 40 to 80 years with symptomatic moderate to severe COPD. Patients were randomized 5:3 to ensifentrine or placebo. Moderate to severe exacerbation rates, time to first exacerbation, and subgroup outcomes were assessed. Post hoc analyses evaluated the risk of transitioning from infrequent to frequent exacerbator status.

Study Findings

Among 1,549 participants (975 ensifentrine; 574 placebo), baseline demographics and disease characteristics were similar between groups. Concomitant maintenance bronchodilator use was common (62%), and 18% of patients received inhaled corticosteroids.

Ensifentrine reduced the rate of moderate to severe exacerbations by 41% (rate ratio, 0.59; 95% CI, 0.43-0.80; P < .001) and significantly prolonged time to first exacerbation (hazard ratio, 0.59; 95% CI, 0.44-0.81; P < .001). The number needed to treat to prevent one exacerbation annually was 6.25.

Across all prespecified demographic and clinical subgroups—including age, sex, race, smoking status, chronic bronchitis, background therapy, COPD severity, and blood eosinophil strata—ensifentrine consistently favored reduced exacerbation rate and risk. A numerical delay in transitioning from Global Initiative for Chronic Obstructive Lung Disease (GOLD) group B to group E was also observed (hazard ratio, 0.64; 95% CI, 0.41-1.01).

Clinical Implications

According to the study authors, these findings suggest that ensifentrine provides clinically meaningful reductions in exacerbation burden across a wide spectrum of symptomatic patients with COPD. The broad consistency of effect across subgroups indicates potential utility regardless of eosinophil levels, baseline maintenance therapy, or exacerbation history. Authors noted that these results support ensifentrine as an option for patients requiring additional or alternative nonsteroidal antiinflammatory treatment strategies.

Expert Commentary

“In a pooled analysis of the ENHANCE phase 3 clinical trials, ensifentrine treatment was shown to significantly reduce the rate of moderate and severe exacerbations and increase the time until the first exacerbation in patients with moderate to severe COPD,” researchers concluded.

Reference
Sciurba FC, Christenson SA, Rheault T, et al. Effect of dual phosphodiesterase 3 and 4 inhibitor ensifentrine on exacerbation rate and risk in patients with moderate to severe COPD. CHEST. 2024;167(2). doi:10.1016/j.chest.2024.07.168